ZNF556 Inhibitors
Chemical inhibitors of ZNF556 operate by targeting various pathways that are essential for the protein's activity. PD98059 and U0126 are inhibitors that specifically target the MAPK/ERK pathway. PD98059 accomplishes this by impeding the function of MEK, which in turn prevents the phosphorylation and consequent activation of ERK. Similarly, U0126 inhibits both MEK1 and MEK2, leading to a blockade in the activation of ERK. These actions can result in a reduction of ZNF556 activity if it relies on ERK phosphorylation. Additionally, SP600125 and SB203580 disrupt the MAPK pathway by selectively inhibiting the JNK and p38 MAP kinase, respectively. SP600125's inhibition of JNK can diminish JNK-mediated phosphorylation processes that may be vital for ZNF556's function. SB203580's selective inhibition of p38 MAP kinase can also lead to a decrease in the activity of ZNF556, provided that p38 MAP kinase contributes to its phosphorylation state.
Further, LY294002 and Wortmannin are inhibitors that target the PI3K/AKT signaling pathway. LY294002 is a potent inhibitor of PI3K, which cuts off the upstream signals that would typically lead to the activation of AKT and subsequent phosphorylation events. Wortmannin achieves a similar outcome, preventing PI3K-related signaling that might otherwise enhance ZNF556 activity. Rapamycin, an mTOR pathway inhibitor, impedes processes involved in cell growth and proliferation, which may be connected to ZNF556 regulation. Inhibitors like Gefitinib and Erlotinib act on the EGFR tyrosine kinase, blocking downstream pathways, including those that could activate ZNF556. Sorafenib targets multiple kinases, including those in the RAF family, which are part of the MAPK signaling pathway. By inhibiting RAF, Sorafenib can affect the phosphorylation state or regulation of ZNF556. Lastly, Dasatinib and Imatinib inhibit Src family kinases and BCR-ABL tyrosine kinase, respectively, which can prevent activation of signaling pathways that regulate ZNF556's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is involved in the MAPK/ERK pathway. By inhibiting MEK, PD98059 prevents phosphorylation and activation of ERK, which in turn could inhibit the activity of ZNF556 if ERK phosphorylation is crucial for ZNF556's function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is known to inhibit MEK1 and MEK2, key components of the MAPK/ERK pathway. Inhibition of these kinases prevents activation of downstream ERK, potentially inhibiting ZNF556 activity if ZNF556 is regulated by ERK-dependent phosphorylation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is a part of the MAPK pathway. By inhibiting JNK, SP600125 can reduce JNK-mediated phosphorylation events that might be necessary for the functional activity of ZNF556. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which could play a role in the phosphorylation of proteins such as ZNF556. Inhibition of p38 MAP kinase could therefore lead to a decrease in ZNF556 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), which is upstream of the AKT signaling pathway. By inhibiting PI3K, LY294002 can block the AKT pathway activity, possibly reducing the phosphorylation and activity of ZNF556 if PI3K signaling influences its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can prevent PI3K-related signaling. Inhibition of PI3K by Wortmannin could lead to a reduction in phosphorylation and activity of ZNF556 by limiting upstream signals required for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and can inhibit the mTOR pathway, which is involved in cell growth and proliferation. Inhibition of mTOR by Rapamycin could diminish ZNF556 activity if ZNF556 is regulated by signaling pathways that involve mTOR. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor and by inhibiting EGFR, it can block the downstream signaling cascades such as MAPK, PI3K/AKT, and JNK which may be responsible for the regulation and activation of ZNF556. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the activation of several signal transduction pathways. This inhibition may reduce ZNF556 activity by blocking pathways that contribute to its functional state. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets multiple kinases including RAF, which is part of the MAPK signaling pathway. By inhibiting RAF, Sorafenib could decrease ZNF556 activity if RAF kinase activity affects the phosphorylation state or regulation of ZNF556. | ||||||